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A  Adenosine 
ADAR  Adenosine deaminases acting on RNA 
AhR  Aryl hydrocarbon receptor 
AsO   Antisense locked nucleic acid/DNA oligonucleotides 
A-to-I  Adenosine-to-inosine 
C  Cytidine 
CCK-8  Cell counting kit-8 
cDNA  Complementary deoxyribonucleic acid 
CYP   Cytochrome P450  
DHFR   Diydrofolate reductase  
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dsRNA  Double-stranded ribonucleic acid 
EDTA  Ethylenediamine-N,N,N’,N’-tetraacetic acid 
FBS  Fetal bovine serum 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
G   Guanosine 
IgG  Immunogloblin G 
I  Inosine 
mRNA  Messenger ribonucleic acid 
miRNA  MicroRNA 
MRE  MicroRNA recognition element 
NADPH  Nicotinamide adenine dinucleotide phosphate 
PAGE  Polyacrylamide gel electrophoresis 
PCR  Polymerase chain reaction 
Pre-miRNA  Precursor microRNA 
 Pri-miRNA  Primary microRNA 
RNA  Ribonucleic acid 
RT  Reverse transcription 
SD  Standard deviation 
SDS  Sodium dodecyl sulfate  
siRNA  Small interfering RNA 
snRNA  Small nuclear RNA 
TCDD   2,3,7,8-Tetrachlorodibenzo-p-dioxin  
Tris  Tris(hydroxymethyl)aminomethane 
WST-8                   2-(2-Methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)- 
2H-tetrazolium monosodium salt 
U Uridine 






RNA editing is a post-transcriptional process that alters the nucleotide sequence of 
RNA transcripts. In animals, the most common type of RNA editing is deamination of 
adenosine (A) into inosine (I), A-to-I RNA editing (Wagner et al., 1989; Gallo and 
Galardi, 2008). Since much of the cellular machinery treats ‘I’ as a guanine (G) 
nucleotide, the conversion of nucleotides possibly changes amino acid sequence, 
splicing, microRNA (miRNA) targeting or miRNA maturation (Farajollahi and Maas, 
2010). A-to-I RNA editing is catalyzed by adenosine deaminases acting on RNA 
(ADAR) enzymes (Kim et al., 1994; Gerber et al., 1997). They convert ‘A’ in double-
stranded RNA (dsRNA) structures into ‘I’ by hydrolytic deamination (Fig. 1). There are 
three members of the ADAR family in vertebrates: ADAR1, ADAR2, and ADAR3 (also 
called ADAR, ADARB1, and ADARB2, respectively) (Bass et al., 1997). ADAR1 and 
ADAR2 are ubiquitously expressed in various tissues and have RNA editing activity. 
Whereas, there is no evidence to support the enzymatic activity of ADAR3. (Nishikura, 
2010). The ADAR1 gene produces two protein isoforms, ADAR1 p110 (110 kDa 
protein) and ADAR1 p150 (150 kDa protein) from different transcription initiation sites 
and start codons. The former is constitutively expressed in the nucleus, whereas the 
latter is localized in both nuclear and cytoplasmic, and induced by interferon (Patterson 
and Samuel, 1995; Desterro et al., 2003).  
In early studies, it was revealed that RNA editing plays important roles in the 
central nervous system (Tariq and Jantsch, 2012). For example, glutamate receptor 
subtype A2 and 5-hydroxytryptamine receptor subtype 2C were known to be subjected 
to RNA editing (Sommer et al., 1991; Lomeli et al., 1994; Burns et al., 1997), and the 
disruption of RNA editing in these genes lead to amyotrophic lateral sclerosis and 
Prader-Willi syndrome, respectively (Kawahara et al., 2004; Morabito et al., 2010). In 
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these cases, A-to-I editing occurs within exons, changing crucial amino acids for protein 
function. In recent years, global RNA editing sites were identified by the availability of 
next generation sequencing-based RNA-Seq in normal and cancer tissues (Liu et al., 
2014). The information is compiled in some databases such as RADAR (http://rnaedit. 
com/). However, the biological significance of RNA editing in humans has not been 
completely elucidated. 
It became apparent that disrupted RNA editing or abnormal ADAR expression are 
associated with several diseases, including cancer, neurological disorders, metabolic 
diseases, viral infections, and autoimmune disorders (Slotkin and Nishikura, 2013). 
However, the biological significance of RNA editing in pharmacokinetics and 
pharmacodynamics is not fully understood. This study sought to clarify the role of RNA 
editing in drug response. In chapter 2, it was investigated whether RNA editing can 
affect aryl hydrocarbon receptor (AhR) and its downstream cytochrome P450 (CYP) 
expression in human liver. In chapter 3, the possibility that RNA editing modulates 
dihydrofolate reductase (DHFR) expression and subsequently affects the cell 
proliferation and sensitivity to methotrexate of breast cancer cells was examined.   










































Fig. 1. A-to-I RNA editing. (A) ADAR enzymes convert ‘A’ to ‘I’ by hydrolytic deamination. Inosine 
was recognized by cellular machinery as if it was guanosine. (B) A-to-I editing occurs in dsRNA and 




Down-regulation of human aryl hydrocarbon receptor 
expression by RNA editing in human liver 
 
ABSTRACT 
A-to-I RNA editing is the most frequent type of post-transcriptional nucleotide 
conversion in humans, and it is catalyzed by ADAR enzymes. In this study, the effect of 
RNA editing on human AhR expression was investigated because the AhR transcript 
potentially forms double-stranded structures, which are targets of ADAR enzymes. In 
human hepatocellular carcinoma-derived Huh-7 cells, the knockdown of ADAR1 
reduced the RNA editing levels in the 3’-untranslsted region (3’-UTR) of AhR transcript 
and increased the AhR protein levels. Interestingly, the knockdown of ADAR1 
enhanced the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-mediated induction of 
CYP1A1, a gene downstream of AhR. It was investigated the possibility that A-to-I 
RNA editing creates miRNA targeting sites in the AhR mRNA, and it was found that the 
miR-378-dependent down-regulation of AhR was abolished by the knockdown of 
ADAR1. These results indicated that the ADAR1-mediated down-regulation of AhR 
could be attributed to the creation of a miR-378 recognition site in the 3’-UTR of AhR. 
The inter-individual differences in the RNA editing levels within the 3’-UTR of AhR in 
a panel of 32 human liver samples were relatively small, whereas the differences in 
ADAR1 expression were large (220-fold). In the panel of human livers, a significant 
inverse association was observed between the miR-378 and AhR protein levels. These 
results suggested that the RNA editing-dependent down-regulation of AhR by miR-378 
contributes to the variability in the constitutive expression of AhR in the human liver. In 
conclusion, this study uncovered, for the first time, that A-to-I RNA editing modulates 













Fig. 2. Graphical abstract of chapter 2. ADAR1 down-regulates AhR expression in human liver cells by 
creating a miR-378 targeting site through A-to-I RNA editing. The down-regulation of AhR affects 




As for RNA editing, early studies were mainly for central nervous system (Tariq 
and Jantsch, 2012). There is little information about the significance of RNA editing in 
the liver. This study investigated the extent of the inter-individual variability in ADAR 
expression in normal human livers and its impact on the expression or function of drug 
metabolizing-related genes, focusing on AhR. The RADAR database identified RNA 
editing sites within its inverted Alu repeats, which can form dsRNA structures, in the 3’-
UTR of human AhR. Because the 3’-UTR generally includes binding sites for miRNA, 
which silences gene expression via translational repression or mRNA degradation 
(Bartel, 2004), it is possible that RNA editing creates or destroys miRNA binding 
site(s), thereby altering expression of target mRNA. AhR is a ligand-activated 
transcription factor that regulates the expression of xenobiotic-metabolizing enzymes, 
including CYP1A1, CYP1A2, and CYP1B1 (Ramadoss et al., 2005). In the present 
study, it was investigated whether ADARs in the human liver can modulate AhR 




MATERIALS AND METHODS 
Chemicals and Reagents. TCDD was purchased from Cambridge Isotope 
Laboratories (Cambridge, MA). The pGL3-promoter vector, phRL-TK vector, 
pTARGET vector and Dual-Luciferase Reporter Assay System were obtained from 
Promega (Madison, WI). Lipofectamine 2000, Lipofectamine RNAiMAX, Silencer 
Select siRNA for human ADAR1 (s1007) (siADAR1), human ADAR2 (s1010) 
(siADAR2), and negative control #1, and miRNA mimics for miR-29a, miR-140, miR-
378, and negative control #1 were obtained from Life Technologies (Carlsbad, CA). 
RNAiso, random hexamer, and SYBR Premix Ex Taq were purchased from Takara 
(Shiga, Japan). ROX was from Stratagene (La Jolla, CA). ReverTra Ace was obtained 
from Toyobo (Osaka, Japan). All of the primers were commercially synthesized at 
RIKAKEN (Nagoya, Japan). Rabbit anti-human AhR polyclonal antibody, mouse anti-
human ADAR1 monoclonal antibody, and mouse anti-human ADAR2 monoclonal 
antibody were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The rabbit 
anti-human GAPDH polyclonal antibody was from IMGENIX (San Diego, CA). IRDye 
680 goat anti-rabbit IgG and goat anti-mouse IgG were obtained from LI-COR 
Biosciences (Lincoln, NE). Restriction enzymes were from New England Biolabs 
(Ioswich, MA). All other chemicals and solvents were of the highest grade 
commercially available. 
 
Cell Cultures. Huh-7, the human hepatocellular carcinoma-derived cell line, was 
obtained from Riken Gene Bank (Tsukuba, Japan).  HeLa, the human cervical 
carcinoma-derived cell line, was obtained from American Type Culture Collection 
(Rockville, MD). Huh-7 and HeLa cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (FBS). All of the cells 
were maintained at 37°C under an atmosphere of 5% CO2 and 95% air. 
 
Expression Plasmid Construction. The cDNA from exon 2 to exon 14 of human 
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ADAR1 p110 was cloned into the pTARGET vector, resulting in the 
pTARGET/ADAR1 p110 plasmid. To construct the ADAR1 p150 expression plasmid, 
the cDNA fragment from exon 1 to exon 3 of human ADAR1 p150 was cloned into the 
pTARGET/ADAR1 p110 vector, resulting in pTARGET/ADAR1 p150. The cDNA 
fragment from exon 3 to exon 12 of human ADAR2 was cloned into the pTARGET 
vector, resulting in pTARGET/ADAR2. 
 
Transfection of siRNA, Expression Plasmid and miRNA Mimics into Huh-7 
Cells, and Preparation of Cell Homogenates or Total RNA. Transfection of siRNA 
and miRNA mimics into Huh-7 cells were carried out as follows: Huh-7 cells were 
seeded into 6-well plates. After 24 h, 5 nM siRNA and/or miRNA mimics were 
transfected into Huh-7 cells using Lipofectamine RNAiMAX. When 1000 ng of the 
pTAEGET vector was transfected, Lipofectamine 2000 was used instead of 
Lipofectamine RNAiMAX. After incubation for 48 h, the cells were harvested and re-
suspended in a small amount of TGE buffer [10 mM Tris-HCl, 20% glycerol, and 1 mM 
EDTA (pH 7.4)] and disrupted by freeze-thawing three times. Total RNA was prepared 
using RNAiso.   
 
Human Livers and Preparation of Genomic DNA, Homogenate and Total 
RNA. Human liver samples from 19 donors were obtained from the Human and Animal 
Bridging (HAB) Research Organization (Chiba, Japan), which is in a partnership with 
the National Disease Research Interchange (NDRI, Philadelphia, PA). Samples from 13 
donors were obtained from autopsy materials that were discarded after pathological 
investigation. The use of the human livers was approved by the Ethics Committees of 
Kanazawa University (Kanazawa, Japan) and Iwate Medical University (Morioka, 
Japan). Homogenates were prepared from the human liver samples by homogenization 
with lysis buffer [50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM EDTA, and 1% 
Nonidet P-40] containing protease inhibitors [0.5 mM (p-amidinophenyl) 
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methanesulfonyl fluoride, 2 μg/ml aprotinin, and 2 μg/ml leupeptin]. The protein 
concentration was determined by the Bradford protein assay reagent (Bio-Rad, 
Hercules, CA) with-globulin as the standard. Total RNA was prepared using RNAiso, 
and the integrity was assessed by estimating the ratio of the band densities of the 28S 
and 18S rRNA. 
 
SDS-PAGE and Western Blot Analysis. The analysis of the AhR, ADAR1 and 
GAPDH protein levels was performed as follows: cell homogenates from Huh-7 cells 
(20 g) were separated by 7.5% SDS-PAGE and transferred to an Immobilon-P transfer 
membrane (Millipore, Billerica, MA). The analysis of the ADAR2 protein levels was 
performed as follows: cell homogenates from Huh-7 cells (50 g) were separated by 
7.5% SDS-PAGE and transferred to a Protran nitrocellulose membrane (Whatman 
GmbH, Dassel, Germany). The membranes were probed with rabbit anti-human AhR 
polyclonal, mouse anti-human ADAR1 monoclonal, mouse anti-human ADAR2 
monoclonal, or rabbit anti-human GAPDH polyclonal antibodies and the corresponding 
fluorescent dye-conjugated secondary antibodies. The band densities were quantified 
with an Odyssey Infrared Imaging system (LI-COR Biosciences). The AhR, ADAR1, 
and ADAR2 protein levels were normalized to GAPDH.  
 
Real-time RT-PCR for AhR. cDNA was synthesized from total RNA using 
ReverTra Ace. The primers for human AhR and CYP1A1 were described previously 
(Iwanari et al., 2002). A 1-L portion of the reverse-transcription product was added to 
a PCR mixture containing 10 pmol of each primer, 12.5 L of the SYBR Premix Ex Taq 
solution, and 75 nM Rox in a final volume of 25 L. The PCR conditions were as 
follows: after an initial denaturation at 95°C for 30 s, amplification was performed by 
denaturation at 94°C for 4 s, annealing, and extension at 62°C for 20 s for 40 cycles. 
Real-time PCR was performed using the Mx3000P (Stratagene, La Jolla, CA) with the 
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MxPro QPCR software. The AhR and CYP1A1 mRNA levels were normalized to those 
of GAPDH as described previously (Tsuchiya et al., 2004). 
 
Assessment of RNA Editing Levels in the 3’-UTR of AhR. To evaluate the 
extent of RNA editing, direct sequence analysis was performed on PCR products. The 
3’-UTR of AhR has everted Alu repeats. The two Alu elements were individually 
amplified by PCR using cDNA or genomic DNA as a template. The following primer 
sets were used to amplify the AluSx or AluSc: AluSx-S (5’-AGC AAG GTT TGG TGC 
AAA GT-3’) and AluSx-AS (5’-GCT CTT CAG CTC TCA TAT CT-3’) or AluSc-S (5’-
CTG AAG AGC TTA GAC ACA TT-3’) and AluSc-AS (5’-CCT CAT GCT GGA AAC 
AAA TT-3’). The PCR mixture consists of the cDNA or genomic DNA, 1× PCR buffer 
[67 mM Tris-HCl, pH 8.8, 16.6 mM (NH4)2SO4, 0.45% Triton X-100, and 0.02% 
gelatin], 1.5 mM MgCl2, 0.2 mM dNTPs, 0.4 µM of each primer, and 0.5 U of Taq 
polymerase (Greiner, Tokyo, Japan) in a final volume of 25 µL. After an initial 
denaturation at 94°C for 3 min, amplification was performed with denaturation at 94°C 
for 30 s, annealing at 58°C for 40 s, and extension at 72°C for 15 s for 35 cycles, 
followed by a final extension at 72°C for 5 min. The PCR product was subjected to 
electrophoresis using a 2% agarose gel. Control experiments without the reverse 
transcriptase were conducted to verify that the amplified products were from the 
reverse-transcribed cDNA rather than from contaminating genomic DNA. Specific 
products were purified and subjected to direct sequencing. The extent of editing is 
represented as a percentage calculated from the ratio of the peak height of ‘G’ over the 
sum of the peak heights of ‘G’ and ‘A’ in the sequencing electropherograms. 
 
Reporter Plasmid Construction. The luciferase reporter plasmids were 
constructed as follows: a fragment from +5168 to +5226 of the 3’-UTR of AhR 
containing the microRNA recognition element (MRE) for miR-378 was amplified by 
PCR using Huh-7 cDNA and was inserted into the pGL3p vector at the Xba I site 
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downstream of the luciferase gene. DNA sequence analyses were performed to 
determine whether the plasmids carried unedited (A) or edited (G) nucleosides at the 
editing sites. Such plasmids were named as pGL3p/MRE(A) and pGL3p/MRE(G), 
respectively. The pGL3p/c-miR-378 vector, which has a sequence that perfectly 
matches that of the mature miR-378, was constructed previously (Mohri et al., 2010).  
 
Luciferase Assay. Various pGL3 luciferase reporter plasmids were transfected 
into HeLa cells with the phRL-TK plasmid. Briefly, the cells were seeded into 24-well 
plates. After 24 h, 190 ng of the pGL3p plasmid, 10 ng of the phRL-TK plasmid and 5 
nM of the miR-378 mimic or control were transfected using Lipofectamine 2000. After 
incubation for 48 h, the cells were re-suspended in passive lysis buffer, and luciferase 
activity was measured on a luminometer using the Dual-Luciferase Reporter Assay 
System.  
 
Determination of Mature miR-378 Levels in Human Livers. The expression 
levels of mature miR-378 in a panel of 32 human livers were determined using the 
TaqMan microRNA assay (Applied Biosystems, Foster City, CA) as reported previously 
(Nakano et al., 2015). The expression levels of miR-378 were normalized to U6 small 
nuclear RNA (U6 snRNA) levels.  
 
Statistical Analyses. Statistical significance was determined by analysis of 
variance followed by Dunnett’s multiple comparisons test or Tukey’s method test. The 
comparison of two groups was made with an unpaired, two-tailed Student’s t-test. 
Correlation analyses were performed by Spearman’s rank method. A value of P < 0.05 
was considered statistically significant. 
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RESULTS 
Down-regulation of AhR Expression by ADAR1. To examine whether ADARs 
regulate human AhR expression, ADAR1 or ADAR2 in Huh-7 cells was knocked down 
by using siRNA. Both ADAR1 p110 and ADAR1 p150 is targeted by siADAR1 used in 
this study. Following transfection with siADAR1 and siADAR2, the knockdown of 
ADAR1 p110 and ADAR2 protein were confirmed (Fig. 3A and B). The ADAR1 p150 
protein was not detected by Western blot analysis. The knockdown of ADAR1 
significantly increased AhR protein levels, but not mRNA levels, whereas the silencing 
of ADAR2 did not affect expression at any level (Fig. 3C and D). These results suggest 
















Fig. 3. Effects of ADAR1 or ADAR2 knockdown on AhR expression levels in Huh-7 cells. ADAR1 p110 
protein (A), ADAR2 protein (B), AhR mRNA (C), and AhR protein (D) levels in Huh-7 cells 48 hr after 
transfection with 5 nM siADAR1, siADAR2 or siControl were determined by Western blotting or real-
time RT-PCR, and were normalized to the GAPDH. The values represent the levels relative to the 
siControl. Each column represents the mean ± SD of three independent experiments. *P < 0.05, **P < 
0.01 and ***P < 0.001. 
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ADAR1 Edits the 3’-UTR of AhR. According to RADAR, there are potential 
RNA editing sites in the 3’-UTR of AhR. To examine whether AhR is actually subjected 
to RNA editing, direct sequencing was performed using AhR genomic DNA and cDNA 
from Huh-7 cells. Because ‘I’ is transcribed as ‘G’ by reverse transcriptase used in RT-
PCR, A-to-I RNA edited sites were detected as overlapping peak of ‘A’ and ‘G’. Within 
the Alu elements in the 3’-UTR of AhR, 38 edited sites were identified (Fig. 4). To 
investigate whether ADAR1 or ADAR2 is responsible for the RNA editing events, 
direct sequence analysis of the AhR cDNA from siADAR1- or siADAR2-transfected 
Huh-7 cells was performed. The RNA editing level of almost all of the editing sites was 
reduced by ADAR1 knockdown, but not by ADAR2 knockdown (Fig. 5A). Typical 
sequencing electropherograms of these RNA edited sites are shown in Fig. 5B. These 















Fig. 4. RNA editing sites in the 3’-UTR of AhR. The nucleotide numbering refers to the 5’ end of the 
mRNA as 1. Square brackets represent Alu elements. Arrows show the RNA editing sites, numbered as 1-




















Fig. 5. Effects of ADAR1 or ADAR2 knockdown on RNA editing levels in the 3’-UTR of AhR in Huh-7 
cells. (A) RNA editing levels in the 3’-UTR of AhR in Huh-7 cells 48 hr after transfection with 5 nM 
siADAR1, siADAR2 or siControl were calculated as described in Materials and Methods (B) 
Representative electropherograms from the direct sequencing. A RNA editing site is shown by numbered 
arrows. The numbers represent the RNA editing sites in the 3’-UTR of AhR indicated in Fig. 4. The 
values represent the levels relative to the siControl. Each column represents the mean ± SD of three 













AhR Expression Was Not Changed by ADAR1 or ADAR2 Over-expression. 
To further investigate the role of RNA editing in AhR expression, ADAR1 p110, 
ADAR1 p150, and ADAR2 were over-expressed in Huh-7 cells by transfection of 
expression plasmid. ADAR1 p110, ADAR1 p150, and ADAR2 were successfully over-
expressed (Fig. 6A and B), but the AhR mRNA and protein levels were not changed 
(Fig. 6C and D). Through sequencing analysis, it was demonstrated that the RNA 
editing levels were mildly increased by the over-expression of the ADAR isoforms (Fig. 
7A and B). These results suggest that the endogenous levels of ADAR1 are sufficient 






















Fig. 6. Effects of the over-expression of ADAR1 p110, ADAR1 p150, or ADAR2 on AhR expression. 
ADAR1 p110 and ADAR1 p150 protein (A), ADAR2 protein (B), AhR mRNA (C), and AhR protein (D) 
levels in Huh-7 cells 48 hr after transfection with 1000 ng of pTARGET/Empty, pTARGET/ADAR1 
p110, pTARGET/ADAR1 p150, or pTARGET/ADAR2 were determined by Western blot or real-time RT-
PCR, and were normalized to GAPDH. The values represent the levels relative to pTARGET/Empty or 
pTARGET/ADAR1 p150. The numbers represent the RNA editing sites in the 3’-UTR of AhR indicated 










































Fig. 7. Effects of over-expression of ADAR1 p110, ADAR1 p150, or ADAR2 on RNA editing levels in 
the 3’-UTR of AhR in Huh-7 cells. (A) RNA editing levels in the 3’-UTR of AhR in Huh-7 cells after 
transfection with 1000 ng of pTARGET/Empty, pTARGET/ADAR1 p110, pTARGET/ADAR1 p150, or 
pTARGET/ADAR2. The editing level was calculated as described in Materials and Methods. (B) 
Representative electropherograms resulting from the direct sequencing. A RNA editing site is shown by 
numbered arrows. The numbers represent the RNA editing sites in the 3’-UTR of AhR indicated in Fig. 4. 
Each column represents the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01 and 







ADAR1 Represses the Induction of Downstream Gene of AhR. It was 
investigated whether the ADAR1-mediated down-regulation of AhR might affect the 
induction of genes downstream of AhR. As shown in Fig. 8, treatment of Huh-7 cells 
with 10 nM TCDD, a ligand of AhR, resulted in a significant increase in CYP1A1 
mRNA levels (3.6-fold). When ADAR1 was knocked down, an enhanced induction 
(6.0-fold) of CYP1A1 mRNA was observed. It was confirmed that the AhR protein 
levels were increased by the silencing of ADAR1 in the presence of DMSO, whereas 
the AhR protein levels in the TCDD-treated cells were lower than in control cells. The 
latter phenomenon could be explained by the fact that the degradation of the AhR 
protein is accelerated by ligand binding through the ubiquitin-proteasome pathway 
(Davarinos and Pollenz, 1999: Ma and Baldwin, 2000). Collectively, these data 





Fig. 8. Effects of ADAR1 knockdown on the induction 
of CYP1A1 in Huh-7 cells. Twenty-four hours after 
transfection with 5 nM siADAR1 (+) or negative 
control #1 (-), Huh-7 cells were exposed to 10 nM 
TCDD (+) or 0.1% DMSO (-). CYP1A1 mRNA, AhR 
and ADAR1 protein levels were determined by real-
time RT-PCR or Western blot analysis and normalized 
to the GAPDH levels. The values are expressed 
relative to the levels observed in the siControl- and 
DMSO- treated cells. Each column represents the 
mean ± SD of three independent experiments.*P < 







RNA Editing of the AhR Transcript Creates miRNA Target Sites. It was 
surmised that ADAR1 negatively regulates AhR expression by creating miRNA target 
sites in the 3’-UTR of AhR mRNA. In silico analysis using miRediTar (http://microrna. 
osumc.edu/mireditar) predicted miR-29a, miR-140, and miR-378 as candidate miRNAs 
whose binding affinity to the edited sequence in the 3’-UTR of AhR was predicted to be 
higher than their affinity to the unedited sequence (Fig. 9A). Transfection of miR-29a 
mimics significantly decreased the AhR mRNA levels, but transfection with miR-140 or 
miR-378 mimics had no effect (Fig. 9B). The AhR protein levels were significantly 
decreased by the over-expression of miR-29a and miR-378, but were not changed by 
miR-140 (Fig. 9C). To investigate whether the miR-29a- or miR-378-dependent down-
regulation of AhR requires ADAR1-mediated RNA editing, Huh-7 cells were co-
transfected with siADAR1 and either miR-29a or miR-378 mimics. The AhR mRNA 
(Fig. 9D) and protein (Fig. 9E) levels were significantly reduced by transfection of miR-
29a mimic regardless of whether ADAR1 was knocked down. Interestingly, the over-
expression of miR-378 significantly decreased the AhR protein levels, and the miR-378-
dependent down-regulation of AhR was abolished by the knockdown of ADAR1 (Fig. 
9E). These results indicated that miR-378 and miR-29a regulate AhR expression in a 
RNA editing-dependent and -independent manner, respectively. To further examine 
whether RNA editing affects the binding of miR-378 to the AhR 3’-UTR, luciferase 
assay was performed using reporter plasmids carrying either an unedited sequence 
(pGL3p/MRE(A)) or an edited sequence (pGL3p/MRE(G)). The luciferase activity of 
the pGL3p/MRE(G) plasmid was slightly but significantly reduced by the over-
expression of miR-378, whereas the luciferase activity of the pGL3p/MRE(A) plasmid 
was not affected (Fig. 9F), indicating that miR-378 recognizes the edited sequence 




































Fig. 9. Effects of RNA editing on the miRNA-dependent down-regulation of AhR in Huh-7 cells.  (A) 
Schematic representation of human AhR mRNA, and the predicted MREs of miR-29a, miR-140 and miR-
378 in edited AhR mRNA. The numbering denotes the 5’ end of the mRNA as 1. Open arrows indicate 
the direction of the Alu elements. Bold letters represent seed sequences. RNA editing sites are shown by 
numbered arrows. AhR mRNA (B and D) and protein (C and E) levels in Huh-7 cells 48 hr after 
transfection with 5 nM miR-29a, miR-140, miR-378 mimic or miControl (B and C) and co-transfection 
with 5 nM siRNA (siADAR1 or siControl) and 5 nM miRNA mimic (miR-29a, miR-140, miR-378 
mimic, or miControl) (D and E) were determined by real time RT-PCR or Western blot analysis, and were 
normalized to GAPDH. The values are expressed relative to the levels in the control cells. (F) Luciferase 
assay using plasmids containing a fragment of the 3’-UTR of AhR. HeLa cells were transfected with the 
reporter plasmids (190 ng) along with the phRL-TK plasmid (10 ng) and the miR-378 mimic or control. 
Firefly luciferase activity for each construct was normalized to Renilla luciferase activity. The values are 
expressed relative to the pGL3-p plasmid. Each column represents the mean ± SD of three independent 
experiments. *P < 0.05, **P < 0.01 and ***P < 0.001. 
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ADAR Protein Levels, AhR RNA Editing and Protein Levels, and miR-378 
Levels in Human Livers. The variability in the ADAR protein levels in the panel of 32 
human liver samples was examined. ADAR1 p110, but not ADAR1 p150 or ADAR2, 
were detected by Western blot analysis (Fig. 10A). A large inter-individual difference 
(220-fold) in the ADAR1 p110 protein levels was observed in human liver samples. To 
investigate whether the large inter-individual difference affects the RNA editing levels 
in the 3’-UTR of AhR, direct sequencing was performed using cDNA samples from the 
human liver samples numbered 1 (which had the lowest ADAR1 p110 protein levels), 6, 
16, and 21 (which had the highest ADAR1 p110 protein levels). The RNA editing levels 
tended to be correlated with ADAR1 p110 expression levels in some RNA editing sites. 
However, the inter-individual difference in the RNA editing levels was relatively small 
compared to that in ADAR1 expression levels (Fig. 10B). To investigate whether the 
small inter-individual variability in RNA editing levels in the human livers was specific 
for AhR, the RNA editing levels in filamin B, β, which has been reported to be edited by 
ADAR1 (Chan et al., 2014), was examined (Fig. 11A). The RNA editing levels were 
correlated with ADAR1 p110 expression, and the inter-individual variability was 
relatively large compared to that of AhR (Fig. 11B). These results suggest that the low 
ADAR1 expression levels in the livers would be sufficient to edit the 3’-UTR of AhR.  
Next, the relationship between the expression levels of AhR mRNA, protein, and 
miR-378 in 32 individual human liver samples was examined. The AhR protein levels 
were not positively correlated with the AhR mRNA levels (Rs = -0.14) (Fig. 12A), 
indicating the involvement of post-transcriptional regulation. Interestingly, as shown in 
Fig. 12B, the miR-378 levels (46-fold) were inversely correlated with the AhR protein 
levels (Rs = -0.57). Collectively, these results suggest that inter-individual differences in 
the RNA editing levels in the AhR transcript are small, but that miR-378 has a 
significant impact on AhR down-regulation and is thus one of the causal factors of the 



















Fig. 10. ADAR protein levels, RNA editing levels in the 3’-UTR of AhR in human livers. (A) ADAR 
protein levels in a panel of 32 human livers were determined by Western blot analysis, and were 
normalized to GAPDH. ND: not detectable. The values are expressed relative to the sample with the 
lowest levels. (B) RNA editing levels in the 3’-UTR of AhR in 4 human liver samples (No.1, 6, 16, and 
21). The editing level was calculated as described in Materials and Methods. Each column represents the 






Fig. 11. RNA editing in filamin B, β 
mRNA in human livers (A) 
Schematic representation of human 
filamin B, β mRNA. (B) RNA 
editing levels in filamin B, β exon 42 
in human liver samples (No. 1, 6, 16 
and 21). The editing level was 
calculated as described in Materials 
and Methods. The numbering 
denotes the 5’ end of the mRNA as 1. 





















Fig. 12. The relationships between (A) AhR protein and AhR mRNA levels; (B) AhR protein levels and 
miR-378 levels in 32 human livers. AhR mRNA or protein levels were determined by real time RT-PCR 
or Western blot analysis and normalized to GAPDH. The levels of mature miR-378 in the human livers 
were determined by real time RT-PCR and normalized to U6 snRNA levels. Data represent the mean of 
two independent experiments. The values are expressed relative to the sample with the lowest levels.
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DISCUSSION 
A-to-I RNA editing is a post-transcriptional modification, which, by causing a 
discrepancy between genomic DNA and its transcript, contributes to the diversity of the 
transcriptome. A-to-I modification in the coding regions of mRNAs can lead to 
functional alterations of the encoded protein (Paschen et al., 1996; Chen et al., 2013). 
However, most A-to-I RNA editing occurs in non-coding regions, such as the UTR and 
miRNA transcripts (Levanon et al., 2004; Peng et al., 2012; Wang et al., 2013). It is 
becoming clear that RNA editing can play an important role in the regulation of the 
RNA interference machinery. miRNAs are transcribed in the nucleus by RNA 
polymerase II as long primary transcripts (pri-miRNAs) containing a stem-loop 
structure. The pri-miRNAs are subsequently cleaved into 70-100 nt precursors (pre-
miRNAs). After they are exported into the cytoplasm, pre-miRNAs undergo secondary 
cleavage, leading to mature miRNA duplexes. The stem-loop structures of the pri-
miRNAs make them favorable targets for ADARs. A-to-I editing events can alter the 
processing of miRNA, thereby affecting miRNA expression (Yang et al., 2006; 
Kawahara et al., 2008). In other cases, A-to-I editing of the miRNA seed sequence could 
change its target selection or binding efficiency (Kawahara et al., 2007). In this study, it 
was examined whether the editing of target mRNA, rather than miRNA, might affect 
mRNA:miRNA binding by altering seed matches. The possibility that miRNA target 
sites can be created or deleted by RNA editing has been proposed (Peng et al., 2012; 
Liang and Landweber, 2007), but studies supporting this hypothesis are very limited 
(Borchert et al., 2009; Wang et al., 2013).  
It was found that the 3’-UTR of AhR in human liver and human hepatocarcinoma-
derived cells is predominantly subjected to RNA editing by ADAR1, rather than 
ADAR2 (Fig. 4, Fig. 5A, and Fig. 10B). Because the 3’-UTR of AhR has everted Alu 
repeats that appear to form matched dsRNA structures, this finding is consistent with a 
previous report that ADAR1 promiscuously targets ‘A’ in perfectly base-paired dsRNA, 
whereas ADAR2 prefers selective sites in dsRNA containing mismatches, bulges, and 
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internal loops (Källman., 2003). Recently, it was revealed that the RNA editing levels 
within reversely oriented Alu repeats are negatively correlated with the distance 
between two Alu elements (Bazak et al., 2014). The distance between the two Alu 
elements in the the 3’-UTR of AhR is relatively short (107 bp). Considering that, 
together with the fact that the two Alu elements can form highly matched dsRNA 
structures, AhR mRNA could be a good substrate of the ADAR enzyme. In Fig. 11, 
RNA editing level in Filamin B, mRNA was determined to investigate whether the 
small inter-individual variability in RNA editing levels in the human livers was specific 
for AhR (Fig. 10B). As the result, the RNA editing level was correlated with ADAR1 
p110 level, and the inter-individual variability was larger than that of AhR (Fig. 11B). 
The RNA editing site in Filamin B,  is not located in Alu element. In addition, in silico 
analysis reveals that the RNA sequence of Filamin B,  forms poorly matched and 
shorter double strand structure than that of AhR, implying that Filamin B,  mRNA 
would be less favorable substrate of the ADAR enzymes. These RNA structural features 
would explain the difference of the inter-individual variability of RNA editing levels 
between AhR and Filamin B, transcript. 
The over-expression of ADAR2 significantly increased the RNA editing levels in 
15 out of 38 editing sites (No. 4, 9, 10, 11, 14, 19, 20, 21, 23, 30, 31, 32, 33, 34, and 
38), although the editing levels in most of the sites were reduced by ADAR1 
knockdown (Fig. 5A and Fig. 7A). ADAR1 and ADAR2 have distinct but overlapping 
target specificities (Bass et al., 1997; Lehmann and Bass, 2007). In addition to the RNA 
structure, the surrounding nucleotides have some influence on recognition by ADARs. 
ADAR1 has a 5’ neighbor preference (A = U > C > G), but no apparent 3’ neighbor 
preference (Riedmann et al., 2010).  The 5’ neighbor preference of ADAR2 (A ≈ U > C 
= G) is similar to that of ADAR1; however, ADAR2 has a 3’ neighbor preference (U = 
G > C = A) (Polson and Bass, 1994). Ten of the above 15 RNA editing sites in the 3’-
UTR of AhR have U or G as the 3’ neighbor (Fig. 4). Therefore, ADAR1 and ADAR2 
both would edit the 3’-UTR of AhR. Although a previous study (Chan et al.,2011) 
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reported that ADAR2 is functionally expressed in normal human livers, hepatic ADAR2 
protein was not detected in this study, even when an antibody from another vendor was 
used (data not shown). Because of the lower expression level of ADAR2 compared to 
ADAR1, the role of ADAR2 in RNA editing in human livers may be only minor.  
By computer analysis, miR-29a, miR-140, and miR-378 were predicted to bind to 
the edited sequences in the 3’-UTR of AhR (Fig. 9A). Through co-transfection of Huh-7 
cells with miRNA mimics and siADAR1, it was revealed that miR-29a and miR-378 
regulate AhR expression in a RNA editing-independent and dependent manner, 
respectively (Fig. 9D and E). Using a luciferase assay, it was demonstrated that the A-
to-I (artificially G) conversion at editing site No. 22 was functional and created the 
binding site for miR-378 (Fig. 9F). No other miR-378 MRE was predicted in the 
unedited AhR mRNA. These results suggest that the miR-378-dependent down-
regulation of AhR requires RNA editing. The 3’-UTR of AhR is highly edited not only 
in Huh-7 cells but also in normal human livers (Fig. 10B), implying that hepatic AhR 
expression can be regulated by miR-378. This is supported by the negative correlation 
between miR-378 and AhR expression in the panel of 32 human livers (Fig. 12B). The 
miR-378 has been shown to function as an oncogene in liver cancer (Ma et al., 2014). In 
addition, miR-378 is functionally expressed in normal liver, where it is reported to 
regulate lipid metabolism (Jeon et al., 2013) and CYP2E1-mediated xenobiotic 
metabolism (Mohri et al., 2010; Nakano et al., 2016). The present study adds new 
insight into the role of miR-378 in the human liver. As for RNA editing-independent 
down-regulation by miR-29a, in silico analysis predicted a potential MRE for miR-29a 
lacking a RNA editing site upstream of the Alu elements (Fig. 13). In support of this 
prediction, a recent study reported that the 3’-UTR of human AhR was directly 
recognized by miR-29a in Huh-7 cells (Kurtz et al., 2015), although a functional MRE 
for miR-29a has not been experimentally identified. miR-29 family members, including 
miR-29a, are known to be down-regulated in human fibrotic livers (Roderburg et al., 
2011). Recently, it was reported that activation of AhR induces hepatic fibrosis by 
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directly regulating pro-fibrotic pathways (Pierre et al., 2014). It would be of interest to 
examine the role of miR-29a-mediated AhR regulation in the development of hepatic 
fibrosis.  
 
                                                                     
Fig. 13. Schematic representation of 
the human AhR mRNA, and a 
predicted MRE of miR-29a in 
unedited AhR mRNA. The 
numbering denotes the 5’ end of the 
mRNA as 1. Open arrows indicate 
Alu elements and directions. Bold 
letters represent seed sequences. 
Finally, it was sought to clarify the significance of the RNA editing-mediated 
regulation of AhR expression. AhR is responsible for the transcriptional regulation of 
xenobiotic-metabolizing enzymes, such as the CYP1 isoforms, UDP-
glucuronosyltransferases, and glutathione S-transferases. This study demonstrated that 
the regulation of AhR expression by RNA editing affects the induction of its 
downstream target, CYP1A1 (Fig. 8). It is known that CYP1A1 levels are associated 
with the levels of AhR and its heterodimeic partner, the AhR nuclear translocator 
(Hayashi et al., 1994). Therefore, RNA editing is one of the key factors regulating the 
expression of xenobiotic-metabolizing enzymes. AhR plays important roles not only in 
regulation of xenobiotic-metabolizing enzymes but also in tumor initiation, promotion, 
and progression (Hayashi et al., 1994).  Accumulating evidence suggests that disrupted 
RNA editing or abnormal ADAR expression is associated with cancer (Slotkin and 
Nishikura, 2010). It is possible that the altered ADAR expression in cancer affects AhR 
expression by changing the levels of AhR mRNA editing. 
In summary, it was demonstrated that A-to-I RNA editing regulates the expression 
of AhR by creating miR-378 binding sites. This mechanism contributes to the inter-
individual variability in AhR expression in human livers. This study is the first to prove 




Up-regulation of human dihydrofolate reductase expression 
by RNA editing in human breast cancer 
 
ABSTRACT 
DHFR plays a key role in folate metabolism, and is a target of methotrexate. An 
increase in cellular expression level of DHFR is one of the mechanisms of tumor 
resistance to methotrexate. The present study investigated a novel possibility that DHFR 
expression is modulated by A-to-I RNA editing. In human breast adenocarcinoma-
derived MCF-7 cells, 26 RNA editing sites were identified in the 3’-UTR of DHFR. 
Knockdown of ADAR1 decreased the RNA editing levels in the 3’-UTR of DHFR, and 
resulted in the decrease of DHFR mRNA and protein levels. In the presence of -
amanitin, a transcriptional inhibitor, the edited DHFR mRNA was more slowly 
degraded than the non-edited mRNA, suggesting that DHFR mRNA are stabilized by 
RNA editing. Thus, it was found that ADAR1 up-regulates DHFR expression by 
stabilization of mRNA. miR-25-3p and miR-125a-3p were predicted, by a 
computational analysis, to bind to the non-edited 3’-UTR of DHFR but not to the edited 
sequence. The decrease in DHFR expression by the knockdown of ADAR1 was restored 
by inhibition of these miRNAs, suggesting that RNA editing destroys the miRNA 
recognition elements to increase DHFR expression. Interestingly, the knockdown of 
ADAR1 promotes cell viability and increased the sensitivity to methotrexate of MCF-7 
cells. ADAR1 expression levels and the RNA editing levels in the 3’-UTR of DHFR in 
breast cancer tissues were higher than those in adjacent normal tissues. Collectively, 
ADAR1 positively regulates the expression of DHFR through RNA editing by 
disrupting the binding of miR-25-3p and miR-125a-3p to the 3’-UTR of DHFR, thus 













Fig. 14. Graphical abstract of chapter 3. ADAR1 up-regulates DHFR expression by destroying miR-25-
3p and miR-125a-3p targeting sites through A-to-I RNA editing, thus enhancing cellular proliferation and 
resistance to methotrexate in human breast cancer cells with high ADAR1 expression but not in those 
with low ADAR1 expression. 
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INTRODUCTION 
DHFR is a key enzyme of folate metabolism. It catalyzes the reduction of 
dihydrofolate to tetrahydrofolate using NADPH as a cofactor. Since tetrahydrofolate is 
essential for de novo purine and thymidylate synthesis required for DNA synthesis, cell 
growth and proliferation, DHFR is a target for chemotherapeutic agents such as 
methotrexate and pemetrexed (Schweitzer et al., 1990; Fowler. 2001; Nazki et al., 
2014). The clinical efficacy of methotrexate is often limited by the acquisition of 
resistance in cancer cells. As the mechanisms of methotrexate resistance, mutations in 
DHFR gene leading to decreased affinity of DHFR protein to methotrexate (Albrecht et 
al., 1972; Jackson et al., 1976; Goldie et al., 1980) and decreased uptake of 
methotrexate due to impaired transport (Hill et al., 1979; Moscow et al., 1995; 
Kobayashi et al., 1998) are known. In addition, over-expression of DHFR protein is 
observed in methotrexate-resistant cells (Assaraf, 2007). DHFR expression is regulated 
by multiple mechanisms (Abali et al., 2008), including gene amplification (Alt et al., 
1978; Dolnick et al., 1979), Sp1 and E2F1-mediated transcriptional regulation (Dynan 
et al., 1986; Slansky et al., 1993), and miRNA-mediated post-transcriptional regulation 
(Mishra et al., 2007; Song et al., 2008; Song et al., 2010). This study, it was sought to 
investigate a possibility that RNA editing might also underlie as the regulation 
mechanism. 
Aberrant ADARs expression has been associated with many human diseases 
including cancer (Slotkin and Nishikura, 2013). A more recent study indicated that 
ADAR1 functions as an oncogene in breast cancer (Fumagalli et al., 2015). It was 
noticed that DHFR has been included in RADAR, and that RNA editing sites were 
identified at the introns 3, 4, and 5 as well as 3’-UTR (http://rnaedit.com/). However, 
the effects of these RNA editing on DHFR expression is unknown. In the present study, 
it was investigated whether RNA editing modulates DHFR expression and subsequently 
affects the cell proliferation and sensitivity to methotrexate of breast cancer cells. 
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MATERIALS AND METHODS 
Chemicals and Reagents. Methotrexate hydrate and folinic acid calcium salt 
hydrate were from Tokyo Kasei (Tokyo, Japan) and Sigma-Aldrich (St. Louis, MO), 
respectively. The pGL3-promoter vector, phRL-TK vector, and Dual-Luciferase 
Reporter Assay System were purchased from Promega (Madison, WI). Lipofectamine 
RNAiMAX, Lipofectamine 2000; Silencer Select siRNA for human ADAR1 (s1007) 
(siADAR1), human ADAR2 (s1010) (siADAR2) and negative control #1 (siControl) 
and miRNA mimics for miR-25-3p and miR-125a-3p and negative control #1 
(miControl) were purchased from Life Technologies (Carlsbad, CA). Antisense locked 
nucleic acid/DNA oligonucleotides (AsO) for miR-25-3p (5’- TCA GTC CGA GAC 
AAG TGC AAT G-3’; locked nucleic acids are underlined), miR-125a-3p (5’-GGC 
TCC CAA GAA CCT CAC CTG T-3’) and for negative control (5’-AGA CUA GCG 
GUA UCU UAA ACC-3’) (AsControl) were commercially synthesized by Gene Design 
(Osaka, Japan). RNAiso, random hexamer, and SYBR Premix Ex Taq were from Takara 
(Shiga, Japan). ROX was purchased from Stratagene (La Jolla, CA). ReverTra Ace was 
purchased from Toyobo (Osaka, Japan). All of the primers were commercially 
synthesized at RIKAKEN (Nagoya, Japan). -Amanitin was purchased from 
Calbiochem (San Diego, CA). The rabbit anti-human DHFR polyclonal antibody 
(ab49881) was from Abcam (Cambridge, MA), and mouse anti-human ADAR1 
monoclonal antibody (sc-5579) and mouse anti-human ADAR2 monoclonal antibody 
(sc-73408) were from Santa Cruz Biotechnology (Santa Cruz, CA). The rabbit anti-
human GAPDH polyclonal antibody (IMG-5143A) was purchased from IMGENIX 
(San Diego, CA). IRDye 680 goat anti-rabbit IgG and goat anti-mouse IgG were from 
LI-COR Biosciences (Lincoln, NE). Cell counting kit-8 (CCK-8) was from Dojin 
Chemical Laboratories (Kumamoto, Japan). Restriction enzymes were from New 
England Biolabs (Ioswich, MA). All other chemicals and solvents were of the highest 
grade commercially available. 
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Cell Cultures. MCF-7, a human breast adenocarcinoma cell line, was obtained 
from the American Type Culture Collection (Manassas, VA). A549, a human lung 
carcinoma cell line, was obtained from the Riken Gene Bank (Tsukuba, Japan). The 
MCF-7 cells were cultured in DMEM supplemented with 0.1 mM nonessential amino 
acid and 10% FBS. The A549 cells were cultured in DMEM supplemented with 10% 
FBS. All of the cells were maintained at 37°C under an atmosphere of 5% CO2 and 95% 
air. 
 
Transfection of siRNA, miRNA Mimic or AsO into MCF-7 Cells and 
Preparation of Cell Homogenates and Total RNA.  The MCF-7 cells were seeded 
into 6-well plates and 5 nM siRNA was transfected using Lipofectamine RNAiMAX at 
the same time. In the case of double transfection, 10 nM miRNA mimic or 10 nM AsO 
was co-transfected with 10 nM siRNA into the cells. After 72 h, the cells were harvested 
and suspended in a small amount of TGE buffer and disrupted by freeze-thawing three 
times. Total RNA was prepared using RNAiso.   
 
SDS-PAGE and Western Blot Analysis. For the analysis of the DHFR, ADAR1, 
and GAPDH protein levels, cell homogenates from MCF-7 cells were separated by 
15%, 7.5% and 10% SDS-PAGE, respectively, and transferred to an Immobilon-P 
transfer membrane (Millipore, Billerica, MA). For the analysis of the ADAR2 protein 
levels, the cell homogenates were separated by 7.5% SDS-PAGE and transferred to a 
Protran nitrocellulose membrane (Whatman GmbH, Dassel, Germany). The membranes 
were probed with rabbit anti-human DHFR polyclonal, mouse anti-human ADAR1 
monoclonal, mouse anti-human ADAR2 monoclonal, or rabbit anti-human GAPDH 
polyclonal antibodies and the corresponding fluorescent dye-conjugated secondary 
antibodies. The band densities were quantified with an Odyssey Infrared Imaging 
system (LI-COR Biosciences). The DHFR, ADAR1 and ADAR2 protein levels were 
normalized to GAPDH.  
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Table 1. Primers for real time RT-PCR
Target gene Accession No. Forward (5'to 3 ') Reverse (5' to 3')
DHFR v1 NM_000791 TCC AGA GAA TGA CCA CAA CC ACG TGT CAC TTT CAA AGT CT
DHFR v2 NM_001290354 TGG CCA CCG CTC AGG TAA AC GTG ATT CAT GGC TTC CTT AT
DHFR v3 NM_001290357 TCC AGA GAA TGA CCA CAA CC GGG TGA TTC ATG GCT TCT TG
DHFR v4 NR_110936 TGG CCA CCG CTC AGG TAA AC AGA ACA CCT GGG TAT CTT AT
ADAR1
a NM_001025107 GCT TGG GAA CAG GGA ATC G CTG TAG AGA AAC CTG ATG AAG CC 
GAPDH
b NM_002046 CCA GGG CTG CTT TTA ACT C GCT CCC CCC TGC AAA TGA
18S rRNA
c NR_003286 GGC CCT GTA ATT GGA ATG AGT C GAC ACT CAG CTA AGA GCA TCG
a
Wang et al. (2013)
b
Tsuchiya et al. (2004)
c
Komagata et al. (2009)
 
 Real-time RT-PCR for DHFR Transcript Variants and ADAR1 mRNA. 
cDNA was synthesized from total RNA using ReverTra Ace. The sequences of the used 
primers are shown in Table 1. A 1-L portion of the reverse-transcription mixture was 
added to a PCR mixture containing 10 pmol of each primer, 12.5 L of the SYBR 
Premix Ex Taq solution, and 75 nM Rox in a final volume of 25 L. Real-time PCR was 
performed using the Mx3000P (Stratagene, La Jolla, CA) with the MxPro QPCR 
software. The PCR condition for DHFR v1 and v4 was as follows: after an initial 
denaturation at 95°C for 30 s, amplification was performed by denaturation at 94°C for 
20 s, annealing/extension at 62°C for 20 s for 40 cycles. The PCR condition for DHFR 
v2 and v3 was as follows: after an initial denaturation at 95°C for 30 s, amplification 
was performed by denaturation at 94°C for 20 s, annealing at 53°C for 20 s, and 
extension at 72°C for 20 s for 40 cycles. The PCR condition for ADAR1 was as 
follows: after an initial denaturation at 95°C for 30 s, amplification was performed by 
denaturation at 94°C for 20 s, annealing/extension at 64°C for 20 s for 40 cycles. The 
levels of DHFR variant transcripts and were normalized to those of GAPDH mRNA 
(Tsuchiya et al., 2004). The ADAR1 mRNA levels in human breast cancer tissues 









Evaluation of RNA Editing Levels in the 3’-UTR of DHFR. For the analysis of 
RNA editing levels, direct sequencing of PCR products was performed. The 3’-UTR of 
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DHFR was amplified by PCR using genomic DNA or cDNA as a template. The 
following primer sets for genomic DNA or cDNA were used to amplify the 3’-UTR of 
DHFR: the forward primer 5’-TTT ATC CAA CTT GAC AGT GG-3’ and the reverse 
primer 5’-CTT CAC CCT TGA TTA TTT GG-3’ or the forward primer 5’-AGC TGC 
TCT ATA GCA AGT CT-3’ and the reverse primer 5’-CTT CAC CCT TGA TTA TTT 
GG-3’. The PCR mixture consists of the genomic DNA or cDNA, 1× PCR buffer, 0.4 
µM of each primer and 0.5 U of Gflex polymerase (TAKARA, Shiga, Japan) in a final 
volume of 25 µL. After an initial denaturation at 94°C for 1 min, amplification was 
performed with denaturation at 98°C for 10 s, annealing at 54°C for 15 s, and extension 
at 72°C for 70 s (genomic DNA) or 40 s (cDNA) for 35 cycles, followed by a final 
extension at 72°C for 5 min. The PCR product was subjected to electrophoresis using a 
0.8% agarose gel. Control experiments without the reverse transcriptase were conducted 
to verify that the amplified products were from the reverse-transcribed cDNA rather 
than from contaminating genomic DNA. Specific products were purified and subjected 
to direct sequencing. The extent of editing was represented as a percentage calculated 
from the ratio of the peak height of ‘G’ over the sum of the peak heights of ‘G’ and ‘A’ 
in the sequencing electropherograms. 
 
Evaluation of the Stability of DHFR mRNA. siRNA was transfected into MCF-
7 cells, as described above. After 36 h, the cells were treated with 10 μg/mL α-amanitin 
an inhibitor of transcription. Total RNA was prepared 0, 6, 12 and 24 hours later. The 
DHFR mRNA level was determined by real-time RT-PCR, as described above. 
 
Reporter Plasmid Construction. To construct the luciferase reporter plasmids, 
fragments from +1901 to +2153 (containing MRE for miR-25-3p (MRE25)) and from 
+2443 to +2569 (containing MRE for miR-125a-3p (MRE125)) of the non-edited 3’-
UTR of DHFR were amplified by PCR using MCF-7 genomic DNA and were inserted 
into the pGL3p vector at the XbaI site downstream of the luciferase gene 
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(pGL3p/MRE25(A) and pGL3p/MRE125(A), respectively). Reporter plasmids 
containing these fragment of the edited 3’-UTR of DHFR were constructed by using 
cDNA from MCF-7 (pGL3p/MRE25(G) and pGL3p/MRE125(G), respectively) as a 
template. DNA sequencing analyses revealed that pGL3p/MRE25(G) carries edited 
nucleotides (G) at RNA editing site No. 1, 2, 3, 5, 7, 8, 10 and 11, and that 
pGL3p/MRE125(G) carries ‘G’ at No. 16, 17, 18, 19, and 20 (refer to Fig. 16A). 
  
Luciferase Assay. Various pGL3 luciferase reporter plasmids were transfected 
into MCF-7 cells with the phRL-TK plasmid. Briefly, the cells were seeded into 24-well 
plates. After 24 h, 190 ng of the pGL3p plasmid, 10 ng of the phRL-TK plasmid and 5 
nM of the miR-25-3p, miR-125a-3p mimic or control were transfected using 
Lipofectamine 2000. After incubation for 48 h, the cells were re-suspended in passive 
lysis buffer, and luciferase activity was measured on a luminometer using the Dual-
Luciferase Reporter Assay System.  
 
Assessment of Cell Viability. To evaluate the cell viability, a WST-8 (2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium 
monosodium salt) assay, which is a modified MTT assay, was performed. siRNA was 
transfected into MCF-7 cells as described above and incubated for 72 h. To investigate 
the effects of folinic acid on ADAR1-induced decrease of cell viability, the siRNA-
transfected MCF-7 cells were incubated in the presence or absence of 200 μM folinic 
acid every 12 h for 72 h. The effects of ADAR1 knockdown on sensitivity of MCF-7 or 
A549 cells to methotrexate were investigated as follows; MCF-7 or A549 cells were 
transfected with 0.5 or 1 nM siRNA, respectively. After 24 h, the cells were treated with 
50 nM methotrexate for 24, 48 and 72 h. CCK-8 reagent was added and the absorbance 
of the medium at 450 nm was measured. The percent cell viability was calculated by 
comparing the absorbance of the treated cells with the control cells. 
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Human Breast Cancer and Adjacent Normal Tissues. Breast cancer and 
adjacent normal tissues were obtained as surgical samples from 19 Japanese patients 
with primary breast carcinoma. The patients (42-77 years old) had not undergone 
chemotherapy (Tsuchiya et al., 2006). This study was approved by the Ethics 
Committee of Kanazawa University (Kanazawa, Japan). Written informed consent was 
obtained from patients. The samples were obtained immediately after resection, divided 
into breast cancer and adjacent normal tissues, and immediately frozen with liquid 
nitrogen. The samples were stored at -80°C until use. Total RNA was prepared using 
RNAiso. 
 
Statistical Analyses. Statistical significance was determined by analysis of 
variance followed by Dunnett’s multiple comparisons test or Tukey’s method test. The 
comparison of two groups was made with an unpaired, two-tailed Student’s t-test. 
Correlation analyses were performed by Spearman’s rank method. A value of P < 0.05 
was considered statistically significant. 
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RESULT 
Up-regulation of DHFR Expression by ADAR. To investigate whether ADAR1 
or ADAR2 regulates human DHFR expression, ADAR1 or ADAR2 expression in MCF-
7 cells was knocked down by using siRNA. The siADAR1 used in this study targets 
both ADAR1 p110 and ADAR1 p150. Following transfection with siADAR1 or 
siADAR2, the significant decrease in ADAR1 p110, ADAR1 p150 or ADAR2 protein 
levels were confirmed (Fig. 15A and B). Next, DHFR mRNA and protein expression 
levels were evaluated. In NCBI database, four different DHFR transcript variants (v1-
v4) were registered (Fig. 15C). Taking the effects of RNA editing in introns on splicing 
into consideration, the expression levels of the four transcripts were determined. The 
knockdown of ADAR1 resulted in significant decrease in all DHFR variant transcripts 
levels (Fig. 15D-G). DHFR protein level was also reduced by the transfection of 
siADAR1 (Fig. 15H). The silencing of ADAR2 significantly decreased the DHFR v2 
mRNA level, but not the other DHFR transcript variants mRNA as well as protein 







































Fig. 15. Effects of ADAR1 or ADAR2 knockdown on DHFR expression levels in MCF-7 cells. ADAR1 
p110 and ADAR1 p150 protein (A), ADAR2 protein (B) in MCF-7 cells 72 h after transfection with 5 nM 
siADAR1, siADAR2 or siControl. (C) Schematic representation of human DHFR transcript variants (v1-
v4). Open rectangles indicate exons. DHFR v1 (D), v2 (E), v3 (F), v4 (G) mRNA, and DHFR protein (H) 
levels in MCF-7 cells transfected with siRNA were determined by Western blotting or real-time RT-PCR, 
and were normalized to the GAPDH. The values represent the levels relative to the siControl. Each 
column represents the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 
0.001. 
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ADAR1 Edits the 3’-UTR of DHFR. The RADAR database of RNA editing 
sites indicates the potential RNA editing in the DHFR intron 3, 4, 5 and 3’-UTR. Given 
that ADAR1 positively regulates DHFR expression regardless of transcript variants, the 
effect of RNA editing in the 3’-UTR rather than the intron on DHFR expression was 
investigated. To investigate whether the 3’-UTR of DHFR is actually subjected to RNA 
editing in breast cancer cells, direct sequence analyses of DHFR genomic DNA and 
cDNA from MCF-7 cells were performed. Because ‘I’ is transcribed as ‘G’ by reverse 
transcriptase used in RT-PCR, A-to-I RNA edited sites were detected as overlapping 
peak of ‘A’ and ‘G’. As the result, 26 edited sites in the 3’-UTR of DHFR were 
identified (Fig. 16A). They were located within inverted Alu repeats, which can form a 
dsRNA structure, a typical target of ADAR enzymes. To investigate whether ADAR1 or 
ADAR2 enzyme is responsible for the RNA editing events, sequence of the DHFR 
cDNA from MCF-7 cells transfected with siADAR1 or siADAR2 was analyzed. Typical 
sequencing electropherograms of these RNA edited sites are shown in Fig. 16B. The 
RNA editing levels of all editing sites were significantly reduced by ADAR1 
knockdown, but not by ADAR2 knockdown (Fig. 16C). These results indicated that 











































Fig. 16. Effects of ADAR1 or ADAR2 knockdown on RNA editing levels in the 3’-UTR of DHFR. (A) 
Schematic representation of human DHFR v1 mRNA and RNA editing sites in the 3’-UTR of DHFR. 
Open arrows indicate the direction of the Alu elements. Arrows show the RNA editing sites, numbered as 
1-26 from 5’ to 3’. (B) Representative electropherograms from the direct sequencing that used genomic 
DNA and cDNA from MCF-7 cells as a template. (C) RNA editing levels in the 3’-UTR of DHFR in 
MCF-7 cells 72 h after transfection with 5 nM siADAR1, siADAR2 or siControl. The editing level was 
calculated as described in Materials and Methods. Each column represents the mean ± SD of three 
independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001. 
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Stabilization of DHFR mRNA by RNA Editing. To determine whether the 
suppression of DHFR mRNA by ADAR1 knockdown is due to accelerated mRNA 
degradation, the effects of ADAR1 knockdown on the stability of the DHFR mRNA 
was examined. In the presence of α-amanitin, the half-life of the DHFR mRNA was 
32.1 h, and it was shortened to 13.1 h by the knockdown of ADAR1 (Fig. 17A), 
suggesting the possibility that a edited DHFR mRNA is more stable than non-edited 
mRNA. To further investigate the difference of stability between non-edited and edited 
DHFR mRNA, direct sequence analysis using cDNA derived from siControl-transfected 
and α-amanitin-treated MCF-7 cells was performed. By treatment of α-amanitin for 24 
h, the height of ‘G’ and that of ‘A’ were increased and decreased, respectively (Fig. 
17B). The levels of DHFR mRNA of which sequence was non-edited or edited in each 
site were calculated by multiplying DHFR level shown in Fig. 17A by the ratio of the 
peak height of ‘A’ or ‘G’, respectively. (Fig. 17C). As the result, it was demonstrated 
that the non-edited DHFR mRNA was dramatically decreased by treatment of α-
amanitin for 24 h, whereas the edited DHFR was not changed. Collectively, it was 






























Fig. 17. Effects of RNA editing on DHFR mRNA stability. (A) MCF-7 cells 36 h after transfection with 5 
nM siADAR1 or siControl were treated with 10 μg/ml of α-amanitin. Total RNA was prepared at 0, 6, 12 
and 24 h later. The DHFR mRNA levels were determined using real-time RT-PCR. The values are 
expressed as relative to the values at 0 h. *P < 0.05 and **P < 0.01 compared with siControl. (B) 
Representative electropherograms from the direct sequencing that used cDNA from MCF-7 cells treated 
with -amanitin for 0 or 24 h as a template. (C) The expression levels of DHFR mRNA which is non-
edited or edited in each editing sites were calculated by multiplying DHFR mRNA expression by the ratio 
of the peak height of ‘A’ or ‘G’, respectively, in the electropherograms resulting from the direct 
sequencing of PCR amplicons that used cDNA from these cells as a template. The values are expressed as 
relative to the values of total DHFR mRNA levels at 0 h. Each column represents the mean (n = 3). 
 
RNA Editing of the DHFR Transcript Destroy miRNA Target Sites. It was 
surmised that the decrease in the extent of RNA editing by ADAR1 knockdown would 
augment the binding of miRNA(s) to the 3’-UTR of DHFR to decrease its expression, 
because the 3’-UTR includes binding sites for miRNA, which down-regulates gene 
expression via translational repression or mRNA degradation (Bartel, 2004). In silico 
analysis using miRediTar (http://microrna.osumc.edu/mireditar) suggested a possibility 
that miR-25-3p and miR-125a-3p, which are reported to be expressed in MCF-7 (Fix et 
al., 2010), would bind to the non-edited sequence in the 3’-UTR of DHFR but not to 
edited sequence (Fig. 18A). To examine whether RNA editing affects the recognition of 
miR-25-3p and miR-125a-3p, luciferase assay was performed using reporter plasmids 
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carrying either a non-edited MRE25 (pGL3p/MRE25(A)), an edited MRE25 
(pGL3p/MRE25(G), a non-edited MRE125 (pGL3p/MRE125(A)) or an edited MRE125 
(pGL3p/MRE125(G) in the 3’-UTR of DHFR. The luciferase activity of the 
pGL3p/MRE25(A) and pGL3p/MRE125(A) plasmid was significantly reduced  (68% 
and 71% of control, respectively) by the over-expression of miR-25 and miR-125a-3p, 
respectively, whereas the decrease of luciferase activity of the pGL3p/MRE25(G) and 
pGL3p/MRE125(G) plasmid were marginal (88% and 91% of control, respectively) 
(Fig. 18B). The decrease in the activity of these plasmids containing edited sequence 
would be irrelevant with the inserted fragment of the 3’-UTR of DHFR, because 
slightly reduction of activities of empty plasmid was observed. This result indicated that 
miR-25-3p and miR-125a-3p recognizes the non-edited but not edited sequence within 
the 3’-UTR of DHFR. To examine the effects of the non-edited DHFR-specific 
regulation by these miRNAs on ADAR1-mediated regulation of DHFR expression, 
over-expression or inhibition experiment was performed by using miRNA mimic or 
AsO, respectively. When miR-25-3p or miR-125a-3p mimic was co-transfected with 
siADAR1, the decrease of DHFR mRNA (Fig. 18C) and protein (Fig. 18D) levels by 
knockdown of ADAR1 was enhanced. On the other hand, inhibition of these miRNA 
function attenuated the knockdown of ADAR1-induced decrease of DHFR expression 
(Fig. 18E and F). These results indicated that the non-edited DHFR-specific down-
regulation by miR-25-3p and miR-125a-3p would be attribute to reduction of DHFR 
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Fig. 18.  Roles of miR-25-3p and miR-125a-3p on ADAR1-dependent regulation of DHFR in MCF-7 
cells.  (A) Schematic representation of human DHFR mRNA, and the predicted MREs of miR-25-3p, 
miR-125a-3p (named as MRE25 and MRE125, respectively) in non-edited DHFR mRNA. Open arrows 
indicate the direction of the Alu elements. Bold letters represent seed sequences. RNA editing sites are 
shown by numbered (refer to fig. 16A) arrows. (B) Luciferase assay using plasmids containing a fragment 
of the 3’-UTR of DHFR. MCF-7 cells were transfected with the reporter plasmids (190 ng) along with the 
phRL-TK plasmid (10 ng) and the miR-25-3p, miR-125a-3p mimic or miControl. Firefly luciferase 
activity was normalized to Renilla luciferase activity. The values are expressed relative to the pGL3-p 
plasmid. DHFR mRNA (C and E) and protein (D and F) levels in MCF-7 cells 72 h after co-transfection 
of 10 nM siRNA (siADAR1 or siControl) and 10 nM miRNA mimic (miR-25-3p, miR-125a-3p mimic, or 
miControl) (C and D) or co-transfection of 10 nM siRNA and 10 nM AsO (As-miR-25a-3p, As-miR-
125a-3p, or AsControl) (E and F) were determined by real time PCR or Western blot analysis, and were 
normalized to GAPDH. The values are expressed relative to the levels observed following the co-
transfection of MCF-7 cells with control. Each column represents the mean ± SD of three independent 
experiments. *P < 0.05, **P < 0.01 and ***P < 0.001. 
 
Decrease in Cell Viability and Resistance to Methotrexate of MCF-7 Cells by 
ADAR1 knockdown. It was demonstrated that the viability of MCF-7 cells was 
significantly decreased by knockdown of ADAR1 (Fig. 19A). Because DHFR has a key 
role in regulating the DNA synthesis by converting dihydrofolate into tetrahydrofolate, 
it was postulated that the decrease in the cell viability would be due to the decreased in 
DHFR protein level. To determine whether this hypothesis is true, folinic acid, a 
molecule that is readily converted into tetrahydrofolate, was added to the siADAR1-
transfected MCF-7 cells (Lladó et al., 2009).  As shown in Fig. 19B, the decreased cell 
viability by ADAR1 knockdown was partially restored by treatment of folinic acid. This 
result suggests that reduction of DHFR protein level is one of the causes of the 
decreased cell viability by ADAR1 knockdown.  
Next, it was investigated whether ADAR1 knockdown enhances sensitivity to 
methotrexate of MCF-7 cells, because it is known that tumors with lower expression of 
DHFR are more sensitive to methotrexate treatment (Salonga et al., 2000; Banerjee et 
al., 2002). In this experiment, the concentration of siADAR1 was decreased to 0.5 nM 
to determine the effects of methotrexate on the cell viability. As the result, after 48 and 
72 h treatment of methotrexate, the cell number was lower in siADAR1-transfected 
cells than in that siControl-transfected cells (Fig. 19C), suggesting that the anti-














Fig. 19.  Effects of ADAR1-dependent regulation of DHFR expression on viability and sensitivity to 
methotrexate of MCF-7 cells. (A) The viability of MCF-7 cells 72 h after transfection with 5 nM 
siADAR1, siADAR2 and siControl. The values are expressed as relative to the values of siControl. (B) 
The viability of siADAR1-transfected MCF-7 cells incubated for 72 h in the presence of 200 M folinic 
acid. The values are expressed as relative to the values of siControl. (C) MCF-7 cells 24 h after 
transfection with 0.5 nM siADAR1 or siControl were treated with 50 nM methotrexate. After 0, 24, 48 
and 72 h, the cell number was evaluated by WST-8 assay. The values are expressed as relative to the 
values of 0 h. Each column and data represents the mean ± SD of three independent experiments. *P < 
0.05 **P < 0.01 and ***P < 0.001. 
 
Higher ADAR1 Expression and RNA Editing Levels in DHFR mRNA in Breast 
Cancer Tissues than in Normal Tissues.  To examine the significance of ADAR1 
expression in RNA editing levels in the 3’-UTR of DHFR in vivo, RNA editing levels in 
DHFR transcript were determined using breast cancer tissues and adjacent normal 
tissues from 19 patients. The expression levels of ADAR1 mRNA tended to be higher in 
breast cancer tissues than in adjacent normal tissues (Fig. 20A) in consistent with a 
previous report (Fumagalli et al., 2015). Next, the RNA editing levels in the 3’-UTR of 
DHFR were evaluated using samples with higher (n = 3) or lower (n = 3) ADAR1 levels 
in cancer tissue than normal tissues. In the former samples, the RNA editing levels in 
DHFR transcript were higher in cancer tissues than in adjacent normal tissues (Fig. 
20B), but not in the latter samples (Fig. 20C). These results suggest that the over-
expression of ADAR1 in breast cancer contributes to hyper-editing of DHFR transcript, 



























Fig. 20.  Expression levels of ADAR1 mRNA and RNA editing levels in the 3’-UTR of DHFR in human 
breast cancer tissues. (A) Expression levels of ADAR1 mRNA in breast cancer tissues and adjacent 
normal tissues obtained from 19 patients were determined by real-time RT-PCR. The expression levels 
were normalized with the 18S rRNA level. Data represent the mean of two independent experiments. The 
values are expressed relative to the sample with the lowest levels. Horizontal bars represent the mean. 
The RNA editing levels in the 3’-UTR of DHFR in breast cancer tissues with higher (No. 1-3) (B) and 
lower (No. 4-6) (C) than adjacent normal tissues. The editing level was calculated as described in 
Materials and Methods. N: normal tissue, T: tumor tissue. Each column represents the mean of two 
independent experiments. *P < 0.05 and **P < 0.01. 
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Discussion 
The possibility that RNA editing may alter miRNA recognition has been proposed 
(Liang and Landweber, 2007; Peng et al., 2012), but the evidence is very limited 
(Borchert et al., 2009; Wang et al., 2013; Nakano et al., 2016). In this study, it was 
examined whether ADAR1 regulates DHFR expression by editing ‘A’s within the 
miRNA binding sites in the 3’-UTR. This finding provides further experimental 
evidence for the role of RNA editing in target recognition by miRNA. 
It was found that ADAR1-mediated RNA editing events occur in the 3’-UTR of 
DHFR in MCF-7 cells and breast cancer tissues (Fig. 16B, C, Fig. 20B and C). The 
RNA editing sites were identified in inverted Alu repeats, which can form perfectly 
matched dsRNA structure. These results were consistent with a recent report showing 
that ADAR1, but not ADAR2, is the main RNA editing enzyme for reversely oriented 
Alu repeats (Stellos et al., 2016). In this study, knockdown of ADAR2 marginally 
increased RNA editing levels in the 3’-UTR of DHFR. It is known that 
homodimerization is important for functions of both human ADAR1 and ADAR2, 
whereas heterodimerization between ADAR1 and ADAR2 has been shown to decrease 
editing activity (Deffit and Hundley, 2016). The increased RNA editing levels by 
ADAR2 knockdown may be due to the increase in functional ADAR1 
homodimerization along with decrease in the ratio of heterodimeraization of ADAR1 
and ADAR2.  
It was found that the degradation of DHFR mRNA was facilitated by ADAR1 
knockdown in MCF-7 cells (Fig. 17A). Supporting this result, the higher stability of 
edited DHFR mRNA than non-edited mRNA was observed (Fig. 17C), suggesting that 
RNA editing is the main factor to determine DHFR mRNA degradation rate. The 
underlying mechanism of RNA editing-dependent regulation of DHFR expression was 
investigated focusing on miRNA. By a computer analysis, miR-25-3p and miR-125a-3p 
were predicted to regulate non-edited but not edited DHFR expression (Fig. 18A). The 
non-edited sequence-specific recognition by these miRNAs were experimentally 
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demonstrated by luciferase assay (Fig. 18B). Through co-transfection of siADAR1 with 
miRNA mimics or AsO, it was demonstrated that ADAR1-mediated regulation of 
DHFR requires function of these miRNAs (Fig. 18C-F). miR-25-3p and miR-125a-3p 
have been reported to regulate the expression of Smad7 and breast cancer early onset 
gene 1 in MCF-7 cells, respectively (Smith et al., 2012; Xu et al., 2016), suggesting the 
functional expression of these miRNAs in this cell lines. The present study indicated 
that RNA editing in the 3’-UTR of DHFR would allow DHFR mRNA to escape from 
repression by these miRNAs, leading to elevation of DHFR expression in breast cancer 
cells. To examine whether the decrease in DHFR expression by ADAR1 knockdown is 
fully owing to the function of miR-25-3p and miR-125a-3p, double transfection of 
AsOs for these miRNAs with siADAR1 was performed. As the result, double inhibition 
of these miRNAs could not completely restore the decreased DHFR expression level by 
knockdown of ADAR1 (data not shown), suggesting a possibility that the other factors 
may be also involved in this regulatory mechanism. It is highly possible that miR-92a-
3p and miR-92b-3p have the similar role as miR-25-3p, because these miRNAs shares 
the seed sequence. Beside miRNAs, a recent study revealed that RNA editing within 
reversely oriented Alu repeats in the 3’-UTR of cathepsin S enables to recuit RNA-
binding protein human antigen R to this region, thereby increasing its mRNA stability 
(Stellos et al., 2016). Further studies are needed to uncover the significance of these 
factors on DHFR expression.  
Another possible mechanism for the decrease in DHFR expression by ADAR1 
knockdown is induction of negative regulators such as miRNA for DHFR expression, 
because A-to-I editing events can alter the processing of miRNA, thereby affecting 
miRNA expression (Yang et al., 2006; Kawahara et al., 2008). It would be of interest to 
investigate the effects of RNA editing on expression levels of miRNAs including miR-
24, miR-192 and miR-215, which were reported to regulate DHFR expression (Mishra 
et al., 2007; Song et al., 2008; Song et al., 2010).    
By ADAR1 knockdown, the viability of MCF-7 cells were decreased (Fig. 19A) in 
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consistent with a previous report (Fumagalli et al., 2015), suggesting the oncogenic 
ability of ADAR1 in breast cancer cells. The decrease was partially restored by 
treatment of folinic acid, which can supply folic acid derivatives (Fig. 19B). These 
results suggest that DHFR is likely to be one of the downstream editing targets that are 
responsible for the oncogenic function of ADAR1. In addition, as shown in Fig. 19C, 
ADAR1 knockdown enhanced methotrexate sensitivity of MCF-7 cells although the 
extent was small. A previous report indicated that MCF-7 cells are more resistant to 
methotrexate (IC50 value: 114 nM) than other cell lines (IC50 value: 6-38 nM) because 
MCF-7 cells have mutations in reduced folate career gene, leading to decrease in 
methotrexate uptake (Yoon et al., 2010). Thus, we tested the effects of ADAR1 
knockdown on sensitivity to methotrexate of A549 cells which have relatively lower 
IC50 value of methotrexate: 38 nM. In accordance with the report by Yoon et al. (2010), 
the anti-proliferative effect of methotrexate on A549 cells (52.9% of control at 72 hr) 
(Fig. 21) was stronger than that of MCF-7 cells (82.8% of control at 72 hr) (Fig. 19C). 
However, the effect of ADAR1 knockdown on sensitivity to methotrexate in A549 cells 
(73.0% of control at 72 h) was as small as that in MCF-7 cells (77.1% of control at 72 
h) (Fig. 21), indicating that the contribution of ADAR1 to resistance is not different 
between MCF-7 and A549 cells. It has been reported that dihydrofolate reductase like 1, 
whose gene is known as pseudogene DHFRP4, is expressed and has same function as 
DHFR in folate metabolism (McEntee et al., 2011). It is possible that this enzyme may 
complement the decreased expression of DHFR by ADAR1 knockdown, leading to 
residual resistance to methotrexate in these cell lines. 
 
Fig. 21. Effects of ADAR1-dependent regulation of 
DHFR expression on sensitivity to methotrexate of 
A549 cells. A549 cells 24 h after transfection with 1 
nM siADAR1 or siControl were treated with 50 nM 
methotrexate. After 0, 24, 48 and 72 h, the cell number 
was evaluated by WST-8 assay. The values are 
expressed as relative to the values of 0 h. Each column 
and data represents the mean ± SD of three independent 
experiments. ***P < 0.001. 
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Accumulating evidence suggests a role of ADAR-mediated A-to-I RNA editing in 
cancer development and progression (Slotkin and Nishikura, 2013). Interestingly, the 
role of RNA editing differs among cancer types. In brain tumors, ADAR1 and ADAR2 
are down-regulated, leading to a global reduction in A-to-I editing, which is functionally 
required for brain tumor development (Paz et al., 2007). In contrast, ADAR1 has been 
reported to be up-regulated in hepatocellular carcinoma (Chan et al., 2014) and 
esophageal squamous cell carcinoma (Qin et al., 2014) and cell-based assay revealed 
that ADAR1 can induce tumorigenic phenotypes in these cancer cells. More recently, it 
was revealed that ADAR1 expression and global editing frequency were higher in breast 
tumors compared to normal tissues (Fumagalli et al., 2015). In consistent with the 
report, the higher expression levels of ADAR1 in breast cancer tissues than in adjacent 
normal tissues was observed in the present study, although the difference was not 
significant owing to the large inter-individual variability in the expression (Fig. 20A). 
ADAR1 gene is located on chromosome 1q, of which amplification is often observed in 
breast cancer tissues (Chen et al., 1989). Fumagalli et al. (2015) reported that ADAR1 
expression levels in breast cancer are correlated with the extent of gene amplification as 
well as the expression of signal transducer and activator of transcription 1 (as a proxy 
for interferon response). The inter-individual difference in ADAR1 expression in human 
breast cancer tissues would be explained in part by these factors. 
 In conclusion, it was clarified that DHFR is post-transcriptionally regulated through 
ADAR1-mediated RNA editing, affecting cell proliferation and sensitivity to 
methotrexate of breast cancer cells. This study could provide new insights into the 
regulatory mechanism of DHFR expression and the role of RNA editing in methotrexate 
response. ADAR1 may be a potential anti-tumor target for use with anti-folate agents 







RNA editing is an important post-transcriptional modulation to affect diverse gene 
expression and function. A-to-I RNA editing is the most frequent type of RNA editing 
in mammals, and is catalyzed by ADAR enzymes. The biological significance of RNA 
editing in drug response remains poorly understood. The purpose of this study was to 
clarify the impact of the RNA editing on expression of pharmacokinetics and 
pharmacodynamics-related genes, focusing on AhR and DHFR. 
In chapter 2, the effects of RNA editing in the 3’-UTR of AhR on its expression in 
human liver cells was examined. AhR is a ligand-dependent transcription factor that 
regulates the expression of xenobiotic-metabolizing enzymes, including CYP1A1, 
CYP1A2 and CYP1B1. In 32 human liver samples, significant positive correlation was 
not observed between AhR mRNA and AhR protein levels, suggesting that post-
transcriptional regulation plays an important in AhR expression. Cell-based experiments 
demonstrated that AhR is negatively regulated by ADAR1-mediated RNA editing. The 
induction of CYP1A1, a downstream gene of AhR, by TCDD was augmented by 
ADAR1 knockdown, suggesting that RNA editing affected the expression of P450 
isoform. The underlying mechanism for regulation of AhR expression by RNA editing 
was investigated, focusing on miRNA. The miR-378-dependent downregulation of AhR 
was abolished by knockdown of ADAR1, indicating that the mechanism of the ADAR1-
mediated downregulation of AhR would be attributed to the creation of the miR-378 
recognition site in the 3’-UTR of AhR. The inter-individual differences in the RNA 
editing levels within the 3’-UTR of AhR in a panel of 32 human liver samples were 
relatively small, whereas the differences in ADAR1 expression were large (220-fold). In 
the human liver samples, a significant inverse association was observed between the 
miR-378 and AhR protein levels, suggesting that the RNA editing-dependent down-
regulation of AhR by miR-378 contributes to the variability in the constitutive hepatic 
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expression of AhR. This study uncovered that A-to-I RNA editing modulates the AhR 
and its downstream P450 expression in human liver. 
In chapter 3, potential role of RNA in the regulation of DHFR expression in human 
breast cancer cells was investigated. It was found that the 3’-UTR of DHFR was 
subjected to RNA editing in a breast cancer-derived MCF-7 cells. Experiments using 
MCF-7 cells demonstrated that DHFR is positively regulated by ADAR1-mediated 
RNA editing which stabilizes DHFR mRNA. Luciferase assay revealed that miR-25-3p 
and miR-125a-3p can bind to the 3’-UTR of non-edited DHFR but not to the edited 
sequence. The decrease in DHFR expression by knockdown of ADAR1 was restored by 
inhibition of these microRNAs, suggesting that RNA editing by ADAR1 destroys these 
miRNA recognition elements to increase DHFR expression. The knockdown of ADAR1 
decreased cell viability and increased the sensitivity to methotrexate of MCF-7 cells. 
These results demonstrated that ADAR1 positively regulates the expression of DHFR 
through RNA editing by disrupting the binding of miRNAs to the 3’-UTR of DHFR, 
thus enhancing cellular proliferation and resistance to methotrexate. The RNA editing 
levels in breast cancer tissues were higher than in normal tissues, suggesting that over-
expression of ADAR1 in breast cancer contributes to hyper-editing of DHFR transcript, 
which may increase the DHFR expression levels. 
     In conclusion, it was clarified that RNA editing modulates AhR and DHFR 
expression by creating or destroying miRNA recognition sites in their 3’-UTRs, 
respectively. These studies are the first to demonstrate the biological significance of 
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